China
Africa
Explore chapters and articles related to this topic
Current and future topical treatments for psoriasis
Published in M. Alan Menter, Caitriona Ryan, Psoriasis, 2017
Shivani Nanda, Linda Stein Gold
INCB018424 is a Janus kinase 1/2 (JAK 1/2) inhibitor that is being studied in a topical cream formulation. JAKs are involved in signal transduction and lead to the production of many of the proinflammatory cytokines implicated in psoriasis. In a vehicle-controlled, phase IIb study, INCB018424 cream in three different strengths (0.5%, 1.0%, 1.5%) was applied twice daily for 28 days. A dose–response curve was seen with the best improvement with the 1.5% concentration used twice daily. Mild to moderate local irritation reactions were seen in 20% of patients treated with INCB018424 compared with 28% of patients treated with vehicle.79
Accelerate development of topical cream drug product using a common platform base formulation
Published in Pharmaceutical Development and Technology, 2020
Dimple Modi, Himanshu Sharma, Gossett Campbell
The platform formulation approach is a unique concept where different placebo formulations were manufactured using different solvent combination, different emulsifier combination, and different emulsifier ratios. In this manuscript, we have identified nine stable platform cream formulations containing a combination of three solvent systems and three emulsifier combinations. The platform cream formulations met the critical quality attributes of cream-like consistency, low separation index values (<0.1), and a uniform droplet size distribution with less than 1 µm droplet size throughout the samples (Raposo et al. 2014). The significance of this work is that the platform topical cream formulation approach will be a useful tool to formulation scientists in early formulation design and development to accelerate active topical drug product development timelines by 3–6 months.
Insights into future therapeutics for atopic dermatitis
Published in Expert Opinion on Pharmacotherapy, 2018
Taylor Edwards, Nupur U. Patel, Amy Blake, Samantha Prabakaran, Danielle Reimer, Steven R. Feldman, Lindsay C. Strowd
VTP-38543, a Liver X Receptor (LXR) selective agonist is another topical agent with potential benefit for AD. When LXRs are activated, genes involved in lipid synthesis and cholesterol transport are upregulated leading to decreased inflammation, improved barrier function, and more rapid repair of damaged skin [21]. In mouse models, transepidermal water loss was decreased with the topical use of LXR agonists, supporting the idea that barrier function is improved when LXRs are bound [21]. VTP-38543 in topical cream formulation completed a phase 1/2 trial evaluating safety and efficacy in adults with mild-to-moderate AD but results are not yet published (NCT02655679).